$NVCR filed an 8-K with results (Item 2.02) at 7:00 AM ET on Thu, Oct 29.
Vote
NVCR
NovoCure Limited$12.92CS band Caution
−$1.06 (7.48%) Thu · Closed $13.11
−$0.19 (1.45%) ☀ Pre-Market
Oct 30, 8:33 AM ET
About NVCR
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Why it moved
Q3 net revenue $193.4M (+16% YoY), EPS -$0.09; FY guidance $736M-$743M, adjusted EBITDA $24M-$34M · per SEC filing
Sources: SEC filing
AI generated · May contain errors
From SEC filing · Not investment advice
Sign up free to see this.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about NVCR?
Board · 0 threads
Open board ›Community opinions, not advice. Posts with a target get a receipt. How receipts work ›